Compare · ISR vs LH
ISR vs LH
Side-by-side comparison of IsoRay Inc. (ISR) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ISR and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH is the larger of the two at $21.68B, about 424.4x ISR ($51.1M).
- LH has hit the wire 7 times in the past 4 weeks while ISR has been quiet.
- LH has more recent analyst coverage (25 ratings vs 1 for ISR).
- Company
- IsoRay Inc.
- Labcorp Holdings Inc.
- Price
- $0.38-1.03%
- $263.82-0.44%
- Market cap
- $51.1M
- $21.68B
- 1M return
- -
- -0.86%
- 1Y return
- -
- +14.64%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 0
- 7
- Recent ratings
- 1
- 25
IsoRay Inc.
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest ISR
- IsoRay Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Williamson Robert F Iii bought $90,710 worth of shares (127,206 units at $0.71), increasing direct ownership by 60% to 338,761 units (SEC Form 4)
- Williamson Robert F Iii bought $78,474 worth of shares (135,879 units at $0.58), increasing direct ownership by 180% to 211,555 units (SEC Form 4)
- Puhlmann Markus bought $139,888 worth of shares (280,000 units at $0.50), increasing direct ownership by 26% to 1,375,425 units (SEC Form 4)
- Williamson Robert F Iii bought $25,478 worth of shares (51,996 units at $0.49), increasing direct ownership by 220% to 75,676 units (SEC Form 4)
- SEC Form D filed by IsoRay Inc.
- IsoRay Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by IsoRay Inc.
- IsoRay Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- SEC Form 424B5 filed by IsoRay Inc.
Latest LH
- Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
- Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
- Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
- SEC Form DEFA14A filed by Labcorp Holdings Inc.
- SEC Form DEF 14A filed by Labcorp Holdings Inc.
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp Declares Quarterly Dividend
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Announce First Quarter Financial Results on April 30, 2026
- SEC Form 4 filed by Schechter Adam H